Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016', provides in depth analysis on Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted pipeline therapeutics. The report provides comprehensive information on the Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - The report reviews Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics and enlists all their major and minor projects - The report assesses Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Overview 7 Therapeutics Development 8 Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Stage of Development 8 Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Therapy Area 9 Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Indication 10 Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Companies 13 Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 17 Assessment by Molecule Type 18 Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Companies Involved in Therapeutics Development 19 Daiichi Sankyo Company, Limited 19 Intellipharmaceutics International Inc. 20 Mapi Pharma Ltd. 21 Pfizer Inc. 22 Prismic Pharmaceuticals, Inc. 23 Yuhan Corporation 24 Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Drug Profiles 25 (palmidrol + pregabalin) - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 gabapentin - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 mirogabalin besylate - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 NVA-1309 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 pregabalin - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 pregabalin CR - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 pregabalin CR - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 pregabalin ER - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 pregabalin IR - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 pregabalin XR - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Dormant Projects 40 Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Discontinued Products 41 Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Featured News & Press Releases 42 Jan 11, 2016: Pfizer Voluntarily Recalls Lyrica Capsules 42 Nov 25, 2015: Pfizer Reports Top-Line Results from a Phase 3 Study of LYRICA (pregabalin) Capsules CV in Adults with Post-Traumatic Peripheral Neuropathic Pain 42 Sep 10, 2015: Actavis Wins Patent Case Over Generic Lyrica 42 Mar 30, 2015: Intellipharmaceutics Submits and was Granted a Pre-IND Meeting Request with the US FDA for Its Regabatin XR (Pregabalin Extended Release Capsules) Drug Candidate 43 Mar 12, 2015: Pfizer Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA Capsules CV As A Treatment For Adolescents With Fibromyalgia 43 Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin 43 Dec 18, 2014: Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia 44 Dec 10, 2014: Commonly Prescribed Drug for Lower Back Pain Not Effective 45 Nov 12, 2014: Pfizer to present data on LYRICA (pregabalin) capsules at ACR 2014 Annual Meeting 46 Nov 10, 2014: US Court Issues Final Order and Judgment Approving Class Action Settlement Related To Neurontin 47 Oct 22, 2014: Intellipharmaceutics Reports Positive Results from a Series of Phase I Clinical Trials of Regabatin XR (Pregabalin Extended-Release) 47 Aug 12, 2014: Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy Lyrica Studies Conducted in China 48 Jun 02, 2014: Pfizer Agrees To Pay $325m To Settle Neurontin Case 49 Feb 21, 2014: Pfizer's Pregabalin Receives CHMP Positive Opinion 49 Dec 09, 2013: US Supreme Court Refuses To Hear Pfizer's Appeal On Marketing Of Neurontin 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 51 Disclaimer 52
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Products under Development by Companies, H2 2016 14 Assessment by Monotherapy/Combination Products, H2 2016 15 Number of Products by Stage and Mechanism of Action, H2 2016 16 Number of Products by Stage and Route of Administration, H2 2016 17 Number of Products by Stage and Molecule Type, H2 2016 18 Pipeline by Daiichi Sankyo Company, Limited, H2 2016 19 Pipeline by Intellipharmaceutics International Inc., H2 2016 20 Pipeline by Mapi Pharma Ltd., H2 2016 21 Pipeline by Pfizer Inc., H2 2016 22 Pipeline by Prismic Pharmaceuticals, Inc., H2 2016 23 Pipeline by Yuhan Corporation, H2 2016 24 Dormant Projects, H2 2016 40 Discontinued Products, H2 2016 41
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
